Latest news with #ARES
Yahoo
2 days ago
- Business
- Yahoo
Vulcan Value Partners: Ares Management Corporation (ARES) is One of the Highest-Quality Alternative Asset Managers
Investment management company Vulcan Value Partners recently released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The firm does not focus on short-term outcomes, whether positive or negative, and believes it can enhance the potential long-term returns and reduce risk. In the quarter, the Large Cap Composite returned 7.0% net of fees and expenses, the Small Cap Composite returned 6.7% net, the Focus Composite returned 9.5% net, the Focus Plus composite returned 8.8% and the All-Cap Composite returned 8.1% net. For more information on the fund's best picks in 2025, please check its top five holdings. In its second quarter 2025 investor letter, Vulcan Value Partners highlighted stocks such as Ares Management Corporation (NYSE:ARES). Founded in 1997, Ares Management Corporation (NYSE:ARES) is an alternative asset manager. The one-month return of Ares Management Corporation (NYSE:ARES) was 7.52%, and its shares gained 22.07% of their value over the last 52 weeks. On July 16, 2025, Ares Management Corporation (NYSE:ARES) stock closed at $179.92 per share, with a market capitalization of $58.758 billion. Vulcan Value Partners stated the following regarding Ares Management Corporation (NYSE:ARES) in its second quarter 2025 investor letter: "Ares Management Corporation (NYSE:ARES) is a global, diversified alternative asset manager with a leading private credit franchise. Market sentiment began turning negative during the first quarter of this year and bottomed out during the tariff related sell off in early April. We added to our position during this time. Ares is unique within the alternative space as they have a history of growing more quickly during times of dislocation. There are many reasons for this growth but some of the most important are the defensiveness of credit and Ares's ability to play offense in down markets. We continue to view the alternative asset management industry positively due to long-term secular growth tailwinds and long-term locked up capital that leads to annuity-like fee streams. We believe Ares is one of the highest quality alternative asset managers and has one of the best combinations of value stability and value growth in the industry." A close up of a senior financial advisor reviewing a portfolio and making recommendations for an investor. Ares Management Corporation (NYSE:ARES) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 42 hedge fund portfolios held Ares Management Corporation (NYSE:ARES) at the end of the first quarter, which was 43 in the previous quarter. While we acknowledge the potential of ARES as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Ares Management Corporation (NYSE:ARES) and shared the list of best fast growth stocks to invest in. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-07-2025
- Business
- Yahoo
TD Cowen Raises Ares Management (ARES) Price Target on Strong Platform Confidence
Ares Management Corporation (NYSE:ARES) ranks among the . On June 30, TD Cowen reaffirmed its Buy rating on Ares Management Corporation (NYSE:ARES) but raised its price target from $199 to $204. The TD Cowen-sponsored investor meetings on June 25 strengthened the firm's confidence in Ares Management's platform capabilities, which led to the price target rise. The meetings, according to TD Cowen, reinforced the company's faith in the 'compounding nature' of Ares Management's platform and boosted assurance that management can reach and even surpass the key performance metrics set forth at the company's 2024 Investor Day. The firm cited Ares Management's 'Incumbency Advantage' in particular as an important contributor to its optimistic outlook. Ares Management Corporation (NYSE:ARES) is an alternative asset management with operations in Asia, Europe, and the United States. The company is divided into different divisions, including the Real Estate Group, the Private Equity Group, the Direct Lending Group, and the Tradable Credit Group. While we acknowledge the potential of ARES as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
Yahoo
02-07-2025
- Business
- Yahoo
Ares Management Corporation Schedules Earnings Release and Conference Call for the Second Quarter Ending June 30, 2025
NEW YORK, NY / / July 2, 2025 / Ares Management Corporation announced today that it will report earnings for the second quarter ending June 30, 2025 on Friday, August 1, 2025 prior to the opening of the New York Stock Exchange. Ares Management Corporation will hold its webcast/conference call on the same day at 11:00 a.m. (Eastern Time) to discuss its second quarter ending June 30, 2025 financial results. All interested parties are invited to participate via telephone or the live webcast, which will be hosted on a webcast link located on the Home page of the Investor Resources section of our website at Please visit the website to test your connection before the webcast. Domestic callers can access the conference call by dialing +1 (800) 579-2543. International callers can access the conference call by dialing +1 (785) 424-1789. All callers are asked to dial in 10-15 minutes prior to the call and to reference the conference ID ARESQ225 so that name and company information can be collected. For interested parties, an archived replay of the call will be available through September 1, 2025 to domestic callers by dialing +1 (800) 727-1367 and to international callers by dialing +1 (402) 220-2669. An archived replay will also be available through September 1, 2025 on a webcast link located on the Home page of the Investor Resources section of our website. About Ares Management CorporationAres Management Corporation (NYSE:ARES) is a leading global alternative investment manager offering clients complementary primary and secondary investment solutions across the credit, real estate, private equity and infrastructure asset classes. We seek to provide flexible capital to support businesses and create value for our stakeholders and within our communities. By collaborating across our investment groups, we aim to generate consistent and attractive investment returns throughout market cycles. As of March 31, 2025, Ares Management Corporation's global platform had approximately $546 billion of assets under management, with operations across North America, South America, Europe, Asia Pacific and the Middle East. For more information, please visit Investor Relations:irares@ Media:media@ SOURCE: Ares Management Corporation View the original press release on ACCESS Newswire
Yahoo
24-06-2025
- Business
- Yahoo
Ares Management Strikes $2.3 Billion Deal to Buy 20% Stake in Eni Unit Plenitude
Ares Management (ARES) will acquire a minority stake in Italian energy group Eni's (E) energy transi
Business Wire
19-06-2025
- Business
- Business Wire
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025
LYON, France--(BUSINESS WIRE)--Regulatory News: Following the submission of the Marketing Authorization Application to the EMA for our lead asset, we are excited to advance Xervyteg® toward commercialization — a potential world first for a microbiota therapeutic in oncology. Share MaaT Pharma (EURONEXT: MAAT – the 'Company'), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today provides a business update and highlights its key milestones expected for the second half of 2025. 'Following the submission of the Marketing Authorization Application to the EMA for our lead asset, Xervyteg ®, earlier this month, we are excited to advance Xervyteg ® toward commercialization — a potential world first for a microbiota therapeutic in oncology — and are now fully focused on progressing registration activities across Europe', said Hervé Affagard, CEO and co-founder of MaaT Pharma. 'This marks a major step in confirming our commitment to address high unmet medical needs and, importantly, it serves as a stepping stone toward international expansion, as we aim to bring our therapies to patients worldwide" Pipeline highlights In Hemato-Oncology Acute Graft-versus-Host Disease (aGvHD) – Xervyteg ® (MaaT013) In January 2025, the Company announced positive topline results from the pivotal Phase 3 ARES Study evaluating Xervyteg ® (MaaT013) in aGvHD. The study met its primary endpoint with a significant gastrointestinal overall response rate at Day 28 of 62% and demonstrates the unprecedented efficacy of Xervyteg ® as third-line treatment of aGvHD with gastrointestinal involvement (GI-aGvHD) consistent with communicated Early Access Program results. On June 02, 2025, the Company announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its lead drug candidate MaaT013, under the registered brand name of Xervyteg ®. If approved, the Marketing Authorization would establish Xervyteg ® as the first microbiota therapeutic approved by the EMA, the first one in hemato-oncology worldwide and the first approved therapy in third-line GI-aGvHD. On June 13, 2025, the Company presented positive updated data in Early Access Program for 173 patients at the 2025 annual EHA Congress supporting the high efficacy and good safety profile of Xervyteg ®. This dataset confirms the breakthrough potential of Xervyteg ® for aGvHD patients with limited treatment options. Final results from the pivotal ARES study, including 12-month overall survival data, are expected before the end of 2025 and will be incorporated into the filing dossier. The potential marketing authorization could be delivered around mid-2026, enabling the start of the commercialization of Xervyteg ® in Europe. MaaT Pharma is advancing discussions with potential partners to accelerate the commercialization plan across Europe. MaaT Pharma primarily focuses on the commercialization of its most advanced asset with the completion of regulatory steps in Europe, and dedicated preparation activities for the European launch of Xervyteg ®. In parallel, the Company continues discussions with the FDA to optimize a dedicated pivotal study in the U.S., with the objective of enabling the earliest possible access to Xervyteg ® for U.S. patients. Such a study could be initiated in 2026 (instead of Q4 2025), subject to regulatory confirmation as MaaT Pharma continues watching the evolving regulatory policies and process in the United States. The Company continues the ongoing Early Access Program in the United States, initiated in December 2024. Allogenic Hematopoietic Stem Cell Transplant (allo-HSCT) - MaaT033 Over the past 12 months, three DSMB safety assessments were conducted for MaaT033 in the Phase 2b PHOEBUS randomized trial designed to be pivotal: two routine evaluations and one interim analysis focused on excess mortality. All confirmed a favorable safety profile and recommended continuation of the trial without modifications. The last patient enrollment in the trial is anticipated for mid-2026 while the 1-year OS results are expected in H2 2027. In Immuno-Oncology Xervyteg ® and MaaT033 – Proof-of-Concept trials using the MET-N platform (donor derived conducted as Investigator-Sponsored Trials (ISTs). In March 2024, the Company completed patient recruitment for the Phase 2a randomized clinical trial (NCT04988841) (PICASSO) sponsored by AP-HP in Paris and in collaboration with INRAE and Institut Gustave Roussy, evaluating Xervyteg ® in combination with immune checkpoint inhibitors (ICI), ipilimumab (Yervoy ®) and nivolumab (Opdivo ®), in metastatic melanoma patients. The Company provided its Xervyteg ® drug candidate and placebo and contributes to the microbiome profiling of patients using its proprietary gutPrint ® AI research engine, while the trial investigator-sponsor handled recruitment, treatment and is overseeing data collection and analysis. Data readout is expected in H2 2025 as previously announced. In May 2024, the Company announced its participation in the IMMUNOLIFE 'RHU' (university hospital trial) program, a consortium including academic partners, such as Institut Gustave Roussy (IGR), a world-renowned center in the field of cancer treatment, and biotech companies. MaaT033 will be tested as a concomitant treatment to cemiplimab (Regeneron), an anti-PD1 therapy, to assess the potential increase in response rate in patients having received antibiotics. This investigator-sponsored, randomized, multicenter Phase 2 trial will evaluate MaaT033 in patients with advanced non-small cell lung cancer (NSCLC), with MaaT Pharma supplying the investigational product. The trial is expected by the sponsor to start mid-2025. MaaT034 – Next-generation drug candidates with co-cultured technology (MET-C platform) In April 2025, the Company presented new preclinical data for MaaT034, its next generation product, showing compelling anti-tumor efficacy results in germ-free mice at the American Association for Cancer Research (AACR) Annual Meeting 2025. Key results included: Metagenomic analysis shows that MaaT034 reproduces the microbial functions of Xervyteg ® MaaT034 improves DC-mediated T cell activation and potentiates anti-tumor effects mediated by anti-PD-1 checkpoint blockade in vitro. 70% of MaaT034 microbial species engraft in mice, ensuring an enduring presence of beneficial bacteria in the gut environment. MaaT034 increases the production of key microbial-derived metabolites such as short-chain fatty acids in germ-free mice. This translates into an improved gastrointestinal physiology as evidenced by gut mucosal restoration. MaaT034 optimizes anti-PD1 mediated activity in tumor-bearing, germ-free mice. While anti-PD1 alone reduced tumor growth by 10%, the combination of anti-PD1 and MaaT034 resulted in a 83.7% tumor growth reduction (compared to a 24.2% reduction when using a single strain of Akkermansia muciniphila bacteria). In Neurodegenerative Diseases In May 2025, MaaT Pharma announced positive final Phase 1b results for MaaT033 in Amyotrophic Lateral Sclerosis (ALS), showing a favorable safety and tolerability profile supported by biomarker and microbiome analyses. Moving forward, the Company is seeking a partner to further advance clinical evaluation in ALS. As a reminder, the Company's Annual General Meeting will take place on Friday, June 20, 2025, at 9:30am CET at the Company's headquarter in France located at 70 avenue Tony Garnier, 69007 Lyon and will also be broadcasted live. A presentation by the management team on recent developments and perspectives will take place from 9:00 to 9:30 a.m. CET, prior to the General Meeting. For more information, please visit the investors section on the Company's website. --- About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. Forward-looking Statements All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as 'target,' 'believe,' 'expect,' 'aim', 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.
